Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,478.50GBp
3:18am EST
Change (% chg)

-82.50p (-1.81%)
Prev Close
4,561.00p
Open
4,531.50p
Day's High
4,531.50p
Day's Low
4,471.50p
Volume
222,944
Avg. Vol
2,424,865
52-wk High
5,377.00p
52-wk Low
3,423.00p

Select another date:

Fri, Nov 11 2016

UPDATE 1-Shire sees opportunity in Asia, aims to double revenue by 2020

* Sees opportunity as China opens consultation on key drugs list

Shire sees opportunity in Asia, aims to double revenue by 2020

SINGAPORE, Nov 11 Shire, a specialist in rare diseases, aims to double Asian sales by 2020, as it targets markets including China, where it hopes to put its haemophilia drugs on a reimbursement list being updated this year for the first time since 2009.

Shire slips on poor sales of hemophilia drugs

LONDON Shire reported a fall in third-quarter sales of hemophilia drugs acquired in its $32 billion Baxalta deal in June, resulting in a rare miss on both the top and bottom lines and sending its shares lower.

UPDATE 2-Shire slips on poor sales of haemophilia drugs

* Shares recover some losses to trade down 1.5 pct (Adds quotes, reaction, updates shares)

Fund manager notches first win in drug patent challenge campaign

A U.S. Patent and Trademark Office tribunal has invalidated most of Shire PLC's patent on its Gattex short bowel syndrome drug, handing hedge fund manager Kyle Bass his first victory in an ongoing campaign of challenging drug patents.

BRIEF-Shire granted EU approval for pancreatic cancer combination therapy

* Granted eu marketing authorization of onivyde, in combination with 5-fluorouracil (5-fu) and leucovorin (lv),for treatment of metastatic adenocarcinoma of pancreas in adult patients who have progressed following gemcitabine-based therapy Source text for Eikon: Further company coverage: (Reporting By UK Bureau)

BRIEF-Shire announces update to vyvanse U.S. labeling

* Shire PLC - Shire announces update to vyvanse (lisdexamfetamine dimesylate) U.S. labeling

BRIEF- Shire plc to become a component of NASDAQ-100 index

* Shire plc will become a component of nasdaq-100 index and nasdaq-100 equal weighted index prior to market open on wednesday, october 19, 2016

BRIEF-Shire Plc says patent trial and appeal board upholds validity of LIALDA patent

* Says patent trial and appeal board upholds validity of LIALDA patent Source text for Eikon: Further company coverage:

BRIEF-Mmenta Pharmaceuticals to regain global development and commercialization rights to M923

* Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire

Select another date: